Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Harbor vs YourHealthRx

Harbor
Graded #86

Higher grade

vs+2.4000000000000057
YourHealthRx
Graded #119

Lower grade

The verdict

Harbor takes it — 72/100 to 69.6/100.

Harbor grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Harbor is a physician-led telehealth platform offering compounded semaglutide (from $99/mo) and compounded tirzepatide (from $149/mo) — among the lowest headline prices in the market.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHarbor +21
74
53
Dose & formulationYourHealthRx +11
64
75
Clinical oversightHarbor +2
89
87
Labs & monitoringYourHealthRx +4
63
67
FulfillmentYourHealthRx +13
81
94
Contract termsHarbor +14
47
33
Harbor · left barYourHealthRx · right bar

The numbers

MetricHarborYourHealthRx
WeighScore72/10069.6/100
GradeCC
Scorecard rank#86#119
Semaglutide$99/mo (starting dose, compounded)$170/mo (compounded)
Tirzepatide$149/mo (starting dose, compounded)$210/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Harbor

Graded #86 · C

Strengths

  • Compounded semaglutide from $99/mo and tirzepatide from $149/mo — among the lowest headline prices in the market
  • LegitScript certified with 4.7-star rating, 94.6% success rate, and 10,000+ verified members
  • 24/7 physician access with ongoing consultations, dosage adjustments, and free discreet shipping
  • 12-Month Money Back Guarantee if you don't reach your weight-loss goal
  • HSA/FSA eligible; no hidden fees, no insurance billed

Where it loses points

  • Compounded medications are not FDA-approved; compounding pharmacy names not publicly disclosed
  • Dietitian support offered only post-program (maintenance phase), not during active treatment
  • State-specific consultation types vary; nationwide availability unconfirmed for all states
  • No labs disclosed; patient portal is a third-party platform (mdintegrations), not native
  • Newer brand; success rate and member counts are on-site claims, not third-party verified
YourHealthRx

Graded #119 · C

Strengths

  • Available in all 50 states and DC through a multi-state (IMLC) licensed clinician network
  • Compounded semaglutide and tirzepatide in two formats - weekly injectable (with B12) or daily oral dissolving tablet
  • Flat subscription price that doesn't change as your dose increases (no titration penalty)
  • Science-forward, clinician-led, with built-in follow-up, lab testing, and a broad peptide and longevity catalog (BPC-157, TB-500, sermorelin, NAD+)
  • Transparent, education-first positioning with published medical disclaimer, privacy, and terms

Where it loses points

  • Eligibility and prescribing run through partner clinical workflows - YourHealthRx is the platform, not the prescriber or pharmacy
  • Compounded medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • The compounding pharmacy partner is not named ('transparent sourcing' claimed but no pharmacy disclosed)
  • Headline prices include a first-month intro rate; ongoing monthly cost is higher (semaglutide ~$170, tirzepatide ~$210)
  • No LegitScript certification displayed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard